https://doi.org/10.4081/cardio.2024.23
Elevated left ventricular end diastolic pressure, chronic pulmonary oedema and valve disease
Published: April 8, 2024
Abstract Views: 701
PDF: 36
HTML: 51
HTML: 51
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
As part of ageing and with increased longevity of older people, there has been a rise of those with increased left ventricular end diastolic pressure (LVEDP) and left ventricular diastolic dysfunction (LVDD). Comorbidities like hypertension, diabetes, chronic kidney disease, coronary artery disease and others appear to be contributing to this. Chronic interstitial pulmonary edema may be a part of the presentation of those with elevated LVEDP/LVDD. Progressive valvular heart disease may also complicate the picture and make clinical decision-making difficult. This case report discusses these issues.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-200.
DOI: https://doi.org/10.1093/eurheartj/ehw128
Banerjee P, Motiwala A, Mustafa HM, et al. Does left ventricular diastolic dysfunction progress through stages? Insights from a community heart failure study. Int J Cardiol 2016;221:850-4.
DOI: https://doi.org/10.1016/j.ijcard.2016.07.091
Mérillon JP, Ennezat PV, Guiomard A, Masquet-Gourgon C, Gourgon R. Left ventricular performance is closely related to the physical properties of the arterial system: landmark clinical investigations in the 1970s and 1980s. Arch Cardiovasc Dis 2014;107:554-62.
DOI: https://doi.org/10.1016/j.acvd.2014.08.001
Banerjee P. Heart failure: a story of damage, fatigue and injury? Open Heart 2017;4:e000684.
DOI: https://doi.org/10.1136/openhrt-2017-000684
Lai-Jing D, Ping-Shuan D, Jing-Jing J. Association between left ventricular end-diastolic pressure and coronary artery disease as well as its extent and severity. Int J Clin Exp Med 2015;8:18673-80.
Rajaram S, Swift AJ, Condliffe R, et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE registry. Thorax 2015;70:382-7.
DOI: https://doi.org/10.1136/thoraxjnl-2014-206088
Hansdottir S, Groskreutz DJ, Gehlbach BK. WHO's in second? A practical review of World Health Organization group 2 pulmonary hypertension. Chest 2013;144;638-50.
DOI: https://doi.org/10.1378/chest.12-2114
Banerjee P. Heart failure with preserved ejection fraction. A clinical crisis. Int J Cardiol 2016;204:198-9.
DOI: https://doi.org/10.1016/j.ijcard.2015.11.170
How to Cite
Banerjee, P. (2024). Elevated left ventricular end diastolic pressure, chronic pulmonary oedema and valve disease. Global Cardiology, 2(1). https://doi.org/10.4081/cardio.2024.23
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Jelena Čelutkienė, Agnė Monika Jakštaitė, Jolita Badarienė, Svetlana Solovjova, Ieva Slivovskaja, Rokas Navickas, Edita Kazėnaitė, Egidija Rinkūnienė, Alma Čypienė, Jonas Misiūra, Ligita Ryliškytė, Aleksandras Laucevičius, Andrew J.S. Coats, Detection of early heart failure with preserved ejection fraction in metabolic syndrome patients detected as part of a national screening program in middle aged subjects , Global Cardiology: Vol. 1 No. 1 (2023)
- Camila Bedo, Juan C. Grignola, Preferential vasodilator effects of levosimendan in resistance pulmonary arteries in a rodent pulmonary embolism model , Global Cardiology: Vol. 2 No. 1 (2024)
- Maryanne Caruana, Miriam Gatt, Oscar Aquilina, Charles Savona Ventura, Victor Grech, Jane Somerville, The impact of maternal congenital heart disease on pregnancy outcomes in Malta: a retrospective study , Global Cardiology: Vol. 1 No. 1 (2023)
- Eirini Flouda, Athena Stefanatou, Tinia Apergi, Intervention options: depression and cardiovascular disease during COVID-19 , Global Cardiology: Vol. 1 No. 1 (2023)
- Kamilu M. Karaye, Idris Y. Mohammed, Okechukwu S. Ogah, Basil N. Okeahialam, Rationale and design for the peripartum cardiomyopathy in Nigeria (PEACE) registry , Global Cardiology: Vol. 1 No. 1 (2023)
- Asija Začiragić, Marija Mikić, Amela Dervišević, Orhan Lepara, Nesina Avdagić, Nermina Babić, Almir Fajkić, Amina Valjevac, Neck-to-height ratio in Bosnian university students according to the 2017 American College of Cardiology/American Heart Association guidelines on hypertension classification , Global Cardiology: Vol. 2 No. 1 (2024)
- Elena Efremova, Alexander Shutov, Adherence to lifestyle therapy in patients with chronic heart failure and comorbidity , Global Cardiology: Vol. 1 No. 1 (2023)
- Rafael Vidal-Pérez, Ewa A. Jankowska, The scientific targets: the myocardium, the vasculature and the body’s response to heart failure , Global Cardiology: Vol. 2 No. 1 (2024)
- Reinaldo B. Bestetti, Rosemary Furlan-Daniel, Luciano P. Pereira, COVID-19 myocarditis , Global Cardiology: Vol. 2 No. 1 (2024)
- Giuseppe M.C. Rosano, Jerneja Farkas, Evolving targets for heart failure: the journey so far , Global Cardiology: Vol. 1 No. 1 (2023)
You may also start an advanced similarity search for this article.
